Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Standardizing REMS Re-Enrollment Procedures

This article was originally published in The Pink Sheet Daily

Executive Summary

Common registration site for participants in REMS was endorsed by several panel members during a joint meeting of the Drug Safety and Risk Management and Dermatologic and Ophthalmic Drugs Advisory Committees.


Related Content

FDA Plans To Improve REMS Effectiveness With Guidance On Goals And Metrics
Could Internet Be Path To Simplifying Participation In REMS?
Setting the Stage: Qnexa and the Power of REMS
REMS Need Metrics For Assessing Success, Burden On Health Care System
REMS Refinement: Does iPLEDGE’s Evolution Have Lessons For Opioids?
Opioid REMS: Sponsors Share Implementation, But Also Give Up Some Control
Abstral REMS Sets Stage For Risk Reduction Plans For Similar Fentanyls
FDA Standardizes REMS Documents For Certain Fentanyl Products
REMS Reform Looks To Be Theme Of PDUFA V: Stakeholders Call For Standardization, Earlier Notice


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts